Patient info Open main menu

Seretide 250 Evohaler – Summary of Product Characteristics (SmPC) for healthcare professionals

Text from the MHRA, as of · About this document

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, other medicines, pregnancy and breast-feeding.

Contains active substances:

Summary of Product Characteristics (SmPC) - Seretide 250 Evohaler

1. Trade Name of the Medicinal Product

Not applicable

2. Qualitative and Quantitative Composition

Not applicable

3. Pharmaceutical Form

Not applicable

Clinical Particulars

4.1. Therapeutic Indications

Not applicable.

4.2. Posology and Method of Administration

Not applicable.

4.3. Contra-indications

Not applicable.

4.4. Special Warnings and Precautions for Use

Not applicable.

4.5. Interactions with other Medicaments and other forms of Interaction

Not applicable.

4.6. Pregnancy and Lactation

Not applicable.

4.7. Effects on Ability to Drive and Use Machines

Not applicable.

4.8. Undesirable Effects

Not applicable.

4.9. Overdose

Not applicable.

Pharmacological Properties

5.1. Pharmacodynamic Properties

Not applicable.

5.2. Pharmacokinetic Properties

Not applicable.

5.3. Preclinical Safety Data

Not applicable.

Pharmaceutical Particulars

6.1. List of Excipients

Not applicable.

6.2. Incompatibilities

Not applicable.

6.3. Shelf Life

Not applicable.

6.4. Special Precautions for Storage

Not applicable.

6.5. Nature and Contents of Container

Not applicable.

6.6. Instruction for Use/Handling

Not applicable.

Administrative Data

7. Marketing Authorisation Holder

Not applicable.

8. Marketing Authorisation Number

Not applicable.

9. Date of First Authorisation/Renewal of Authorisation

Not applicable.

10. Date of (Partial) Revision of the Text

Not applicable.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLPI 15361/0530

MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Seretide 250 Evohaler

Active substances Salmeterol, Fluticasone
Drug group (ATC)
  1. R Respiratory system drugs
    1. R03 Drugs for obstructive airway diseases
      1. R03A Adrenergics, inhalants
        1. R03AK Adrenergics inhalants in combination with corticosteroids or other drugs, excl. anticholinergics
          1. R03AK06 salmeterol and fluticasone
Marketing authorisation PL 18067/0357, PLPI 15361/0530

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.